TNSN08313A1 - Des formes pharmaceutiques resistantes a la modification - Google Patents

Des formes pharmaceutiques resistantes a la modification

Info

Publication number
TNSN08313A1
TNSN08313A1 TNP2008000313A TNSN08313A TNSN08313A1 TN SN08313 A1 TNSN08313 A1 TN SN08313A1 TN P2008000313 A TNP2008000313 A TN P2008000313A TN SN08313 A TNSN08313 A TN SN08313A TN SN08313 A1 TNSN08313 A1 TN SN08313A1
Authority
TN
Tunisia
Prior art keywords
modification
pharmaceutical forms
forms resistant
resistant
prevention
Prior art date
Application number
TNP2008000313A
Other languages
English (en)
Inventor
Sabine Scherer
Wolfgang Fleischer
Christian Leuner
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35987132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN08313(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of TNSN08313A1 publication Critical patent/TNSN08313A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne la prévention de l'utilisation illicite de formes pharmaceutiques d'agonistes. La présente invention concerne en particulier la prévention de l'utilisation illicite de formes pharmaceutiques d'oxycodone.
TNP2008000313A 2006-01-27 2008-07-24 Des formes pharmaceutiques resistantes a la modification TNSN08313A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06001754A EP1813276A1 (fr) 2006-01-27 2006-01-27 Formes de dosage inviolables
PCT/EP2007/050751 WO2007085637A1 (fr) 2006-01-27 2007-01-25 Formes de doses infalsifiables

Publications (1)

Publication Number Publication Date
TNSN08313A1 true TNSN08313A1 (fr) 2009-12-29

Family

ID=35987132

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000313A TNSN08313A1 (fr) 2006-01-27 2008-07-24 Des formes pharmaceutiques resistantes a la modification

Country Status (32)

Country Link
US (4) US20090169626A1 (fr)
EP (4) EP1813276A1 (fr)
JP (2) JP5714215B2 (fr)
KR (2) KR20110122775A (fr)
CN (1) CN101374521B (fr)
AP (1) AP2258A (fr)
AR (1) AR059194A1 (fr)
AU (1) AU2007209290B2 (fr)
BR (1) BRPI0706952A2 (fr)
CA (1) CA2640339C (fr)
CO (1) CO6220959A2 (fr)
CY (1) CY1113122T1 (fr)
DE (1) DE202007019381U1 (fr)
DK (1) DK1986650T3 (fr)
EA (1) EA017635B1 (fr)
ES (1) ES2389223T3 (fr)
GE (1) GEP20125578B (fr)
HK (1) HK1123748A1 (fr)
HR (1) HRP20120619T1 (fr)
IL (1) IL192973A (fr)
MA (1) MA30310B1 (fr)
ME (1) ME01437B (fr)
NZ (1) NZ570358A (fr)
PL (1) PL1986650T3 (fr)
PT (1) PT1986650E (fr)
RS (1) RS52428B (fr)
SG (1) SG169353A1 (fr)
SI (1) SI1986650T1 (fr)
TN (1) TNSN08313A1 (fr)
TW (1) TWI463983B (fr)
WO (1) WO2007085637A1 (fr)
ZA (1) ZA200806965B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50070B (sr) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
DK2425824T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1604666A1 (fr) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
WO2010103039A1 (fr) 2009-03-10 2010-09-16 Euro-Celtique S.A. Compositions pharmaceutiques à libération immédiate comportant de l'oxycodone et du naloxone
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
WO2011009604A1 (fr) 2009-07-22 2011-01-27 Grünenthal GmbH Forme galénique inviolable stabilisée à l’oxydation
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
CN101768164B (zh) * 2010-01-25 2011-09-14 海南数尔药物研究有限公司 一种高纯度的盐酸纳洛酮化合物
ES2606227T3 (es) 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
KR20130030261A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 활성제-무함유 과립 및 그를 포함하는 정제의 제조
KR101858797B1 (ko) 2010-05-10 2018-05-16 유로-셀티큐 에스.에이. 히드로모르폰 및 날록손을 포함하는 제약 조성물
CA2808541C (fr) 2010-09-02 2019-01-08 Gruenenthal Gmbh Forme pharmaceutique inviolable comportant un polymere anionique
WO2012028319A1 (fr) 2010-09-02 2012-03-08 Grünenthal GmbH Forme pharmaceutique inviolable comportant un sel inorganique
AT511581A1 (de) * 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
CA2864949A1 (fr) 2012-02-28 2013-09-06 Grunenthal Gmbh Forme pharmaceutique inviolable comprenant un compose pharmacologiquement actif et un polymere anionique
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
ES2436344B1 (es) * 2012-05-29 2014-08-07 Onedose Pharma, S.L. Composición farmacéutica de diacetilmorfina y naloxona para administración oral
CA2875056C (fr) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methodes de traitement de la surcharge ponderale et de l'obesite
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
CA2913209A1 (fr) 2013-05-29 2014-12-04 Grunenthal Gmbh Forme dosifiee inviolable a profil de liberation bimodale
EP3003279A1 (fr) 2013-05-29 2016-04-13 Grünenthal GmbH Forme pharmaceutique inviolable contenant une ou plusieurs particules
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EA030310B1 (ru) 2013-11-13 2018-07-31 Эро-Селтик С.А. Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2947786A1 (fr) 2014-05-12 2015-11-19 Grunenthal Gmbh Formulation pour capsule a liberation immediate resistant aux manipulations illicites comprenant du tapentadol
WO2015181059A1 (fr) 2014-05-26 2015-12-03 Grünenthal GmbH Microparticules protégées contre une libération massive dans l'éthanol
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
TW201613590A (en) * 2014-09-12 2016-04-16 Purdue Pharma Lp Systems and methods for attenuating opioid-induced euphoria
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2017042325A1 (fr) 2015-09-10 2017-03-16 Grünenthal GmbH Protection contre un surdosage par voie orale à l'aide de formulations à libération immédiate dissuasives d'abus

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (fr) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (fr) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
RS50070B (sr) * 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
EP1041988A4 (fr) * 1997-12-22 2002-03-13 Euro Celtique Sa Procede prevenant l'abus des doses orales d'opioides
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
DE60232417D1 (de) * 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
MXPA04002709A (es) * 2001-09-24 2005-06-06 Johnson & Johnson Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades.
DK2425824T5 (en) * 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
EP1604666A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive

Also Published As

Publication number Publication date
HK1123748A1 (en) 2009-06-26
PL1986650T3 (pl) 2012-11-30
CA2640339A1 (fr) 2007-08-02
PT1986650E (pt) 2012-08-24
CO6220959A2 (es) 2010-11-19
ZA200806965B (en) 2009-07-29
DE202007019381U1 (de) 2012-02-20
IL192973A0 (en) 2009-02-11
US20140094481A1 (en) 2014-04-03
EP2311458A1 (fr) 2011-04-20
TWI463983B (zh) 2014-12-11
CY1113122T1 (el) 2016-04-13
EP1986650A1 (fr) 2008-11-05
TW200808318A (en) 2008-02-16
ES2389223T3 (es) 2012-10-24
CA2640339C (fr) 2013-03-19
EP1986650B1 (fr) 2012-06-13
US20090169626A1 (en) 2009-07-02
KR20110122775A (ko) 2011-11-10
JP2012255019A (ja) 2012-12-27
AU2007209290B2 (en) 2011-03-17
JP2009524626A (ja) 2009-07-02
IL192973A (en) 2014-04-30
AR059194A1 (es) 2008-03-12
RS52428B (en) 2013-02-28
DK1986650T3 (da) 2012-08-13
AU2007209290A8 (en) 2008-09-18
BRPI0706952A2 (pt) 2011-04-12
WO2007085637A1 (fr) 2007-08-02
JP5714215B2 (ja) 2015-05-07
AU2007209290A1 (en) 2007-08-02
US20170348238A1 (en) 2017-12-07
EP2308494A1 (fr) 2011-04-13
CN101374521B (zh) 2016-11-16
CN101374521A (zh) 2009-02-25
NZ570358A (en) 2012-01-12
KR20080091265A (ko) 2008-10-09
HRP20120619T1 (hr) 2012-10-31
US20120101118A1 (en) 2012-04-26
EP1813276A1 (fr) 2007-08-01
ME01437B (fr) 2013-06-20
MA30310B1 (fr) 2009-04-01
EA017635B1 (ru) 2013-02-28
AP2258A (en) 2011-07-21
AP2008004578A0 (en) 2008-08-31
GEP20125578B (en) 2012-07-25
SG169353A1 (en) 2011-03-30
EA200801758A1 (ru) 2009-02-27
SI1986650T1 (sl) 2012-11-30

Similar Documents

Publication Publication Date Title
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
EA200900260A1 (ru) Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
MA31918B1 (fr) Agents et épitopes de liaison à wise
MA30128B1 (fr) Combinaisons pharmaceutiques d'un antagoniste de receptuer d'angiotensine et d'un inhibiteur de nep
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
EA200870268A1 (ru) Устойчивые к раздавливанию таблетки оксикодона, предназначенные для предотвращения случайного неправильного применения и недозволенного употребления
AP2007004095A0 (en) Cxcr4 antagonists for the treatment of hiv infection
FR2900730B1 (fr) Systeme d'inspection de securite de chargement.
MX2011012599A (es) Compuestos polimericos de agentes inmunomoduladores.
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
BRPI0917540A2 (pt) composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
HK1132175A1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
EP1776083A4 (fr) Compositions dentaires soulageant la sensibilite
MX2008002492A (es) Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
ECSP099566A (es) Sal napadisilato de un antagonista muscarínico m3
MX2009006284A (es) Arilpirazoles sustituidos.
BRPI0810774A2 (pt) composição de cuidado oral ou cuidado corporal.
EP1862183A4 (fr) Composition pharmaceutique contenant un médicament à peine soluble dans l'eau
TW200700071A (en) Novel use
WO2006135799A3 (fr) Detection de coproantigenes d'ankylostome
JO2730B1 (en) Medications for the treatment of endometriosis
BRPI0719189A2 (pt) uso de ciclosporinas modificadas